



Published in final edited form as:

AIDS Care. 2014 August ; 26(8): 988–995. doi:10.1080/09540121.2014.897912.

Suboptimal antiretroviral therapy adherence among HIV-infected adults in Guangzhou, China

Kathryn E. Muessig, PhD^{1,2}, Megan M. McLaughlin, MPH², Jing Min Nie³, Weiping Cai, MD³, Heping Zheng, MD^{2,4}, Ligang Yang, MD^{2,4}, and Joseph D. Tucker, MD, MA^{1,2}

¹Department of Medicine, University of North Carolina Chapel Hill School of Medicine, Chapel Hill, NC, USA

²UNC Project-China, Guangdong Provincial STD Control Center, Guangzhou, China

³Department of Infectious Disease, Number Eight Municipal Hospital, Guangzhou, China

⁴Guangdong Provincial STD Control Center, Guangzhou, China

Abstract

Despite China's free antiretroviral treatment (ART) program, there are high rates of treatment failure, large sociodemographic disparities in care outcomes and emerging medication resistance. Understanding patient medication adherence behaviors and challenges could inform adherence interventions to maximize the individual and prevention benefits of ART. This study assessed recent non-adherence and treatment interruption among 813 HIV-infected adult outpatients in Guangzhou, China. Participants completed a behavioral survey, underwent chart review, and were tested for syphilis, gonorrhea, and chlamydia. Factors associated with suboptimal adherence were identified using univariate and multivariate logistic regression. Among 721 HIV-infected adults receiving ART, 18.9% reported recent non-adherence (any missed ART in the past 4 weeks) and 6.8% reported treatment interruption (four or more weeks of missed ART in the past year). Lower education, living alone, alcohol use and being on ART one to three years were associated with recent non-adherence. Male gender, lower education and being on ART one to three years were associated with treatment interruption. ART medication adherence interventions are needed in China that include individualized, long-term adherence plans sensitive to patients' educational and economic situations. These interventions should also consider possible gender disparities in treatment outcomes and address the use of alcohol during ART. Successful ART medication adherence interventions in China can inform other international settings that face similar adherence challenges and disparities.

Keywords

antiretroviral therapy; ART; ARV; adherence; alcohol; China

Correspondence to: Weiping Cai, MD, Department of Medicine, Number Eight People's Hospital of Guangzhou, Guangzhou Medical University, Guangzhou, China. caiwp@163.net; caiwp@vip.tom.com; Kathryn E. Muessig, PhD, Department of Health Behavior, University of North Carolina Gillings School of Global Public Health, CB#7440, Chapel Hill, NC. kmuessig@med.unc.edu.

INTRODUCTION

The HIV Prevention Trials Network 052 generated renewed urgency to optimize patient adherence to antiretroviral therapy (ART) in order to improve individual patient outcomes and reduce forward HIV transmission (Cohen et al., 2011). China embraced HIV treatment as prevention initiatives through its National Free Antiretroviral Treatment Program and a 2012 decision to promote earlier ART initiation (Zhao, Poundstone, Montaner, & Wu, 2012). Amidst rapid ART scale-up, poor medication adherence threatens these initiatives' ability to achieve virologic suppression (Zhang et al., 2009) and reverse increasing medication resistance (Gardner, Burman, Steiner, Anderson, & Bangsberg, 2009) documented in China (Liao et al., 2012) and globally (Gupta et al., 2012).

In 2011, 126,448 of China's estimated 780,000 persons living with HIV were receiving free ART (Ministry of Health People's Republic of China, 2012), however wide disparities in adherence and treatment outcomes have been noted (Xing et al., 2013; Yan et al., 2013; Zhang et al., 2009). As ART expands, a better understanding of patient adherence is urgently needed. This study assessed factors associated with suboptimal adherence among a large sample of HIV-infected individuals in south China.

METHODS

The main study design has been reported in detail (X. B. Wang et al., 2012). Briefly, between April and June 2011, 813 HIV-infected outpatients 18 years of age and older were recruited at the largest HIV clinic in Guangzhou, China for a cross-sectional survey and sexually transmitted disease (STD) testing. Sample size calculation was based on a three month HIV patient population of 10,000 (hospital records), a 95% confidence level and 3.3 confidence interval, resulting in an estimated required sample size of 811. Among 813 eligible individuals recruited, three declined to participate, leaving a final sample of 810. Participants completed a self-administered survey covering sociodemographics, health behaviors and ART. Survey items were based on prior validated tools among HIV patients (Bunnell et al., 2006; Eisele et al., 2009). The questionnaire was field-tested and revised with input from Chinese clinic patients, six clinic physicians and three nurses. Participants provided 2 ml of blood for syphilis testing and 5 ml of urine for gonorrhea and chlamydia testing (see X.B. Wang et al., 2012 for laboratory procedures). Data on ART initiation and recent CD4 count were abstracted from chart reviews. Institutional review boards from the study hospital, Guangdong Provincial STD Control Center, and the University of North Carolina at Chapel Hill approved the study. Participants provided informed consent and received a small gift (\$4 USD equivalent) as remuneration.

ANALYSIS

Two outcomes were assessed: recent non-adherence (missing any days of ART in the past four weeks), and treatment interruption (missing four weeks or more of ART during the past year). Univariate and multivariate associations with each adherence outcome were calculated using logistic regression. A backward elimination process was used to build multivariate models, and a p-value of <0.10 was required for retention in the final model.

Collinearity was assessed using the variance inflation factor. SAS 9.2 (SAS Institute Inc., Cary NC, USA) was used to perform all data analysis.

RESULTS

89% of enrolled participants (721 out of 810) had started ART (Table 1). Participants taking ART ranged in age from 19 to 79 years old, 61.3% were male, 67.5% had education of middle school or lower, under a third were full-time employed, and 40.8% lived alone. Average length of ART was 827 days, but 34.4% had been on ART under one year. Median most recent CD4 count was 282 cells/ μ L. 89.5% of participants reported receiving sexual risk reduction counseling at the start of ART. 17% of participants had not used a condom at last intercourse, and prevalence of any STD was 9.3%. Overall, 20.6% (n=147) of participants reported drinking alcohol in the past month. Among these 79.6% (n=117) drank alcohol several times a month (moderate), while 20.4% (n=30) drank alcohol several times a week or more (heavy).

Recent non-adherence

18.9% (n=136) of participants reported recent non-adherence (Table 2). In the multivariate analysis, lower education, living alone, alcohol use and longer time on ART were associated with recent non-adherence. Lower education was associated with higher likelihood of recent non-adherence as compared to those with some post-secondary education (high school: adjusted odds ratio [aOR] 3.39; 95% confidence interval [CI], 1.32-8.71; middle school: aOR 3.31, 95% CI, 1.36-8.07; primary school: aOR 4.52, 95% CI 1.78-11.45). Those who lived alone were 1.49 times more likely to report recent non-adherence (95% CI, 1.00-2.21). Alcohol use was associated with recent non-adherence for both moderate (aOR 3.76, 95% CI, 1.65-8.55) and heavy (aOR 2.31, 95% CI, 1.44-3.71) consumption. Compared to patients on therapy for less than one year, those on ART for one to three years were more likely to report recent non-adherence (aOR 1.76, 95% CI, 1.10-2.84). This difference was not significant among participants who had been on ART over three years compared to those on therapy for under one year (aOR 1.26, 95% CI, 0.75-2.12).

Treatment interruption

6.8% (n=49) of participants reported treatment interruption in the past year (Table 3). In the multivariate analysis, being male, having lower education, and longer time on ART were associated with greater likelihood of treatment interruption. Men were 2.06 times more likely to report treatment interruption than women (95% CI, 1.07-3.96). Education below high school (middle school: aOR 6.55, 95% CI, 0.87-49.64; primary school aOR 14.31, 95% CI, 1.86-110.27) was associated with higher likelihood of treatment interruption. There was a non-significant trend between time on ART and treatment interruption. Participants who had been on ART for one to three years were 1.91 times more likely to report a treatment interruption compared to those who had been on therapy under one year (95% CI, 0.91-4.01).

DISCUSSION

Among 721 ART-experienced patients in Guangzhou, China we found frequent ART non-adherence and treatment interruptions. Recent non-adherence (18.9%) surpassed the median rate found in a 6-country study (13.3%) (Corless et al., 2012) and rates reported in comparable China-based samples (Corless et al., 2012; L. Li, Ji, Ding, Tian, & Lee, 2012; Sabin et al., 2010; Simoni et al., 2011).

We found a relationship between alcohol use and adherence consistent with the global literature (Azar, Springer, Meyer, & Altice, 2010; Braithwaite & Bryant, 2010) but not identified in earlier Chinese studies (H. Wang et al., 2008; X. Wang & Wu, 2007). Occasional, daily and binge drinking are significantly associated with worse adherence and decreased survival worldwide (Braithwaite et al., 2005; Hendershot, Stoner, Pantalone, & Simoni, 2009) – a serious concern given the portion of our participants who reported alcohol use in the past month (20.6%). China has high levels of binge drinking and alcohol use (Yang et al., 2012), yet prior adherence studies were not adequately powered to examine this relationship. Alcohol use is also associated with high-risk sexual behaviors internationally (Shuper, Joharchi, Irving, & Rehm, 2009) and in China (Q. Li, Li, & Stanton, 2010). Given the 9.3% prevalence of STDs found in our sample, addressing alcohol use among HIV-infected individuals could also improve prevention of STDs and forward HIV transmission.

Participants with lower education had worse ART adherence. Lower education is consistently associated with lower HIV medication adherence across geographic and economic settings (Fogarty et al., 2002; Rachlis, Mills, & Cole, 2011). This relationship is not well-quantified in China though qualitative studies have explored complex economic, employment and education-based barriers to adherence (L. Li et al., 2012; Sabin et al., 2008; Starks et al., 2008). HIV-infected men were more likely than women to report treatment interruptions. This differs from the global literature (Ammassari et al., 2002), but is consistent with Chinese national data (Dou et al., 2011; Zhang et al., 2009) and may be even more pronounced in rural areas (L. Li et al., 2012).

This study has several limitations. First, all recruitment took place in one outpatient setting. This focused recruitment is a result of the centralized HIV care system in Guangzhou. However, our sample has similar sociodemographic and HIV-transmission characteristics as national samples of HIV-infected individuals on ART (Dou et al., 2011; Sabin et al., 2010; Simoni et al., 2011; Zhang et al., 2009). Secondly, we lacked patient profile data on certain factors found to be associated with non-adherence in previous studies, such as medication tolerance, mental health status, and social support (L. Li et al., 2012; Sabin et al., 2008; Starks et al., 2008). As a possible proxy for social support, our finding that participants who lived alone were more likely to report recent non-adherence suggests that more nuanced measures of social support should be included in future adherence studies in China.

Numerous behavioral, pharmacologic and technology-based interventions to improve adherence demonstrate that high levels of patient adherence are difficult to achieve and maintain over time (Bae, Guyer, Grimm, & Altice, 2011; Mills et al., 2006). As ART adherence interventions are being adapted and tested among Chinese patient populations

(e.g. electronic drug monitoring (Sabin et al., 2010), nurse-delivered (Simoni et al., 2011), cognitive behavioral therapy (Shiu et al., 2013)), we urge greater attention to developing individualized, long-term medication adherence plans that are sensitive to patient educational and economic factors, consider possible gender disparities in treatment outcomes, and address alcohol use. Such plans should also address medication persistence for ART-experienced patients, emphasizing the importance of continued treatment support beyond the first year of therapy. These strategic adherence intervention components could support expanded ART for improved clinical outcomes and reduced forward HIV transmission.

Acknowledgments

Supported by the UNC Center for AIDS Research (NIH 5P30AI050410-13), the Doris Duke Charitable Foundation International Medical Student Program, an International Research Scientist Developmental Award (NIH 1K01TW008200-01A1). KE Muessig was supported by an institutional training grant (NIH 5T32AI007001-35). The authors have no conflicts of interest to declare. We would like to thank the nursing staff and Dr. Haolan He at the Guangzhou Municipal No. Eight People's Hospital infectious disease outpatient clinic, Dr. Xuan Hong, and Dr. Cheng Wang at Guangdong Provincial Center for Skin Diseases and STD Control, and Dr. Bunnell and Dr. Eisele for sharing their questionnaires.

REFERENCES

- Ammassari A, Trota MP, Murri R, Castelli F, Narciso P, Noto P, Antinori A. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. *Journal of Acquired Immune Deficiency Syndromes*. 2002; 31(Suppl 3):S123–127. [PubMed: 12562034]
- Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. *Drug & Alcohol Dependence*. 2010; 112(3):178–193. [PubMed: 20705402]
- Bae JW, Guyer W, Grimm K, Altice FL. Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. *AIDS*. 2011; 25(3):279–290. [PubMed: 21239892]
- Braithwaite RS, Bryant KJ. Influence of alcohol consumption on adherence to and toxicity of antiretroviral therapy and survival. *Alcohol Research & Health*. 2010; 33(3):280–287. [PubMed: 23584069]
- Braithwaite RS, McGinnis KA, Conigliaro J, Maisto SA, Crystal S, Day N, Justice AC. A temporal and dose-response association between alcohol consumption and medication adherence among veterans in care. *Alcoholism, Clinical and Experimental Research*. 2005; 29(7):1190–1197.
- Bunnell R, Ekwaru JP, Solberg P, Wamai N, Bikaako-Kajura W, Were W, Mermin J. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. *AIDS*. 2006; 20(1):85–92. [PubMed: 16327323]
- Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Fleming TR. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. *New England Journal of Medicine*. 2011; 365(6):493–505. [PubMed: 21767103]
- Corless IB, Guarino AJ, Nicholas PK, Tyer-Viola L, Kirksey K, Brion J, Sullivan, K M. Mediators of antiretroviral adherence: A multisite international study. *AIDS Care*. 2012; 25(3):364–377. [PubMed: 22774796]
- Dou Z, Xu J, Jiao JH, Ma Y, Durako S, Yu L, Zhang F. Gender difference in 2-year mortality and immunological response to ART in an HIV-infected Chinese population, 2006–2008. *PLoS One*. 2011; 6(8):e22707. [PubMed: 21857947]
- Eisele TP, Mathews C, Chopra M, Lurie MN, Brown L, Dewing S, Kendall C. Changes in risk behavior among HIV-positive patients during their first year of antiretroviral therapy in Cape Town South Africa. *AIDS Behav*. 2009; 13(6):1097–1105. [PubMed: 18846418]

- Fogarty L, Roter D, Larson S, Burke J, Gillespie J, Levy R. Patient adherence to HIV medication regimens: a review of published and abstract reports. *Patient Education and Counseling*. 2002; 46(2):93–108. [PubMed: 11867239]
- Gardner EM, Burman WJ, Steiner JF, Anderson PL, Bangsberg DR. Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. *AIDS*. 2009; 23(9): 1035–1046. [PubMed: 19381075]
- Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DH, Gregson J, Bertagnolio S. Global trends in antiretroviral resistance in treatment-naïve individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. *Lancet*. 2012; 380(9849):1250–1258. [PubMed: 22828485]
- Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: review and meta-analysis. *Journal of Acquired Immune Deficiency Syndromes*. 2009; 52(2):180–202. [PubMed: 19668086]
- Li L, Ji G, Ding Y, Tian J, Lee A. Perceived burden in adherence of antiretroviral treatment in rural China. *AIDS Care*. 2012; 24(4):502–508. [PubMed: 22084972]
- Li Q, Li X, Stanton B. Alcohol use and sexual risk behaviors and outcomes in China: a literature review. *AIDS and Behavior*. 2010; 14(6):1227–1236. [PubMed: 19967440]
- Liao L, Xing H, Dong Y, Qin G, Ma Y, Lu H, Shao Y. Surveys of transmitted HIV drug resistance in 7 geographic Regions in China, 2008-2009. *Clinical Infectious Diseases*. 2012; 54(Suppl 4):S320–323. [PubMed: 22544196]
- Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, Bangsberg DR. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. *The Journal of the American Medical Association*. 2006; 296(6):679–690.
- Ministry of Health People's Republic of China. 2012 China AIDS Response Progress Report. 2012. Retrieved September 1, 2013, from http://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries/ce_CN_Narrative_Report%5B1%5D.pdf
- Rachlis BS, Mills EJ, Cole DC. Livelihood security and adherence to antiretroviral therapy in low and middle income settings: a systematic review. *PLoS One*. 2011; 6(5):e18948. [PubMed: 21589911]
- Sabin LL, Desilva MB, Hamer DH, Keyi X, Yue Y, Wen F, Gill CJ. Barriers to adherence to antiretroviral medications among patients living with HIV in southern China: a qualitative study. *AIDS Care*. 2008; 20(10):1242–1250. [PubMed: 19012083]
- Sabin LL, DeSilva MB, Hamer DH, Xu K, Zhang J, Li T, Gill CJ. Using electronic drug monitor feedback to improve adherence to antiretroviral therapy among HIV-positive patients in China. *AIDS and Behavior*. 2010; 14(3):580–589. [PubMed: 19771504]
- Shiu CS, Chen WT, Simoni J, Fredriksen-Goldsen K, Zhang F, Zhou H. The Chinese Life-Steps Program: A Cultural Adaptation of a Cognitive-Behavioral Intervention to Enhance HIV Medication Adherence. *Cognitive and Behavioral Practice*. 2013; 20(2):202–212. [PubMed: 23667305]
- Shuper PA, Joharchi N, Irving H, Rehm J. Alcohol as a correlate of unprotected sexual behavior among people living with HIV/AIDS: review and meta-analysis. *AIDS and Behavior*. 2009; 13(6): 1021–1036. [PubMed: 19618261]
- Simoni JM, Chen WT, Huh D, Fredriksen-Goldsen KI, Pearson C, Zhao H, Zhang F. A preliminary randomized controlled trial of a nurse-delivered medication adherence intervention among HIV-positive outpatients initiating antiretroviral therapy in Beijing, China. *AIDS and Behavior*. 2011; 15(5):919–929. [PubMed: 20957423]
- Starks H, Simoni J, Zhao H, Huang B, Fredriksen-Goldsen K, Pearson C, Zhang F. Conceptualizing antiretroviral adherence in Beijing, China. *AIDS Care*. 2008; 20(6):607–614. [PubMed: 18576162]
- Wang H, He G, Li X, Yang A, Chen X, Fennie KP, Williams AB. Self-Reported adherence to antiretroviral treatment among HIV-infected people in Central China. *AIDS Patient Care STDS*. 2008; 22(1):71–80. [PubMed: 18095837]
- Wang X, Wu Z. Factors associated with adherence to antiretroviral therapy among HIV/AIDS patients in rural China. *AIDS*. 2007; 21(Suppl 8):S149–155. [PubMed: 18172384]

- Wang XB, Tucker JD, Yang L, Zheng H, Zhang F, Cohen MS, Cai W. Unsafe Sex and STI Prevalence Among HIV-Infected Adults in Guangzhou, China: Opportunities to Deamplify Sexual HIV Transmission. *AIDS and Behavior*. 2012; 17(3):1137–1143. [PubMed: 23054038]
- Xing H, Wang X, Liao L, Ma Y, Su B, Fu J, Shao Y. Incidence and associated factors of HIV drug resistance in Chinese HIV-infected patients receiving antiretroviral treatment. *PLoS One*. 2013; 8(4):e62408. [PubMed: 23638072]
- Yan H, Yang H, Li J, Wei C, Xu J, Liu X, McFarland W. Emerging Disparity in HIV/AIDS Disease Progression and Mortality for Men Who Have Sex with Men, Jiangsu Province, China. *AIDS Behav*. 2013
- Yang L, Zhou M, Sherliker P, Cai Y, Peto R, Wang L, Chen Z. Alcohol drinking and overall and cause-specific mortality in China: nationally representative prospective study of 220,000 men with 15 years of follow-up. *International Journal of Epidemiology*. 2012; 41(4):1101–1113. [PubMed: 22596929]
- Zhang FJ, Dou ZH, Ma Y, Zhao Y, Liu ZF, Bulterys M, Chen RY. Five-Year Outcomes of the China National Free Antiretroviral Treatment Program. *Annals of Internal Medicine*. 2009; 151(4):241–W252. [PubMed: 19687491]
- Zhao Y, Poundstone KE, Montaner J, Wu ZY. New policies and strategies to tackle HIV/AIDS in China. *Chinese Medical Journal*. 2012; 125(7):1331–1337. [PubMed: 22613610]

Table 1
Demographic and clinical characteristics of 721 HIV-infected patients on antiretroviral therapy in Guangzhou, China

| Characteristic | n (%) |
|--|------------|
| Age | |
| 30 years | 127 (17.6) |
| 31 to 40 years | 295 (40.9) |
| 41 to 60 years | 259 (35.9) |
| 61 years | 40 (5.6) |
| Sex | |
| Male | 442 (61.3) |
| Female | 279 (38.7) |
| Residence | |
| Guangzhou | 269 (37.8) |
| Other, Guangdong Province | 443 (62.2) |
| Education | |
| Primary school | 153 (21.2) |
| Middle school | 334 (46.3) |
| High school | 144 (20.0) |
| Vocational school | 56 (7.8) |
| College | 34 (4.7) |
| Employment | |
| Full-time | 223 (31.1) |
| Part-time or temporary | 180 (25.1) |
| Retired | 43 (6.0) |
| No employment | 271 (37.8) |
| Marital status | |
| Single, live alone | 127 (17.6) |
| Cohabiting/married | 451 (62.6) |
| Separated/divorced | 80 (11.1) |
| Widowed | 62 (8.6) |
| Alcohol | |
| Several times a week | 30 (4.2) |
| Several times a month | 117 (16.4) |
| Do not drink | 567 (79.4) |
| Intravenous drug use in the past month | |
| Yes | 26 (3.9) |
| No | 638 (96.1) |
| Most recent sex partner, last three months | |
| Casual partner | 22 (2.7) |
| Steady partner | 328 (80.4) |
| No partner | 69 (16.9) |

| Characteristic | n (%) |
|--|------------|
| Condoms at last intercourse | |
| Yes | 343 (83.1) |
| No | 70 (17.0) |
| HIV transmission route | |
| Homosexual sex | 70 (9.7) |
| Heterosexual sex | 272 (37.8) |
| Intravenous drug use | 138 (19.2) |
| Transfusion | 81 (11.3) |
| Not sure/other | 158 (22.0) |
| Received risk reduction counseling at ART initiation | |
| Yes | 638 (89.5) |
| No | 75 (10.5) |
| Most recent CD4 count | |
| < 200 cells/mm ³ | 216 (30.0) |
| ≥ 200 cells/mm ³ | 505 (70.0) |
| Time on ART | |
| < 1 year | 248 (34.4) |
| 1 to 3 years | 270 (37.5) |
| > 3 years | 203 (28.2) |
| Tested positive, any STD | |
| Yes | 67 (9.3) |
| No | 654 (90.7) |

Table 2
Factors associated with self-reported missed ART in the past month

| Characteristic | Missed ART, past 4 weeks (N=136) n (%) | Unadjusted OR (95% CI) | p-value | Adjusted OR (95% CI) | p-value |
|------------------------|--|------------------------|---------|----------------------|---------|
| Age | | | | | |
| 30 years | 20 (14.7) | 1.00 | | | |
| 31 to 40 years | 60 (44.1) | 1.36 (0.78 – 2.38) | 0.276 | | |
| 41 years | 56 (41.2) | 1.22 (0.70 – 2.13) | 0.490 | | |
| Sex | | | | | |
| Female | 48 (35.3) | 1.00 | | | |
| Male | 88 (64.7) | 1.21 (0.82 – 1.78) | 0.345 | | |
| Residence | | | | | |
| Guangzhou | 52 (38.8) | 1.00 | | | |
| Other, Guangdong | 82 (61.2) | 0.95 (0.64 – 1.39) | 0.783 | | |
| Education | | | | | |
| Post-secondary | 6 (4.4) | 1.00 | | 1.00 | |
| High school | 28 (20.6) | 3.25 (1.29 – 8.20)* | 0.013 | 3.39 (1.32 – 8.71)* | 0.011 |
| Middle school | 65 (47.8) | 3.30 (1.38 – 7.89)* | 0.007 | 3.31 (1.36 – 8.07)* | 0.008 |
| Primary school | 37 (27.2) | 4.33 (1.74 – 10.74)* | 0.002 | 4.52 (1.78 – 11.45)* | 0.002 |
| Employment | | | | | |
| Full-time | 34 (25.4) | 1.00 | | | |
| Part-time or temporary | 42 (31.3) | 1.69 (1.02 – 2.79)* | 0.042 | | |
| Retired | 3 (2.2) | 0.40 (0.12 – 1.38) | 0.148 | | |
| No employment | 55 (41.0) | 1.39 (0.87 – 2.23) | 0.171 | | |
| Cohabiting/married | | | | | |
| Yes | 77 (56.6) | 1.00 | | 1.00 | |
| No | 59 (43.4) | 1.40 (0.96 – 2.05)* | 0.083 | 1.49 (1.00 – 2.21)* | 0.049 |
| Alcohol | | | | | |
| None | 90 (66.7) | 1.00 | | 1.00 | |
| Several times a month | 34 (25.2) | 2.16 (1.36 – 3.41)* | 0.001 | 3.76 (1.65 – 8.55)* | 0.002 |

| Characteristic | Missed ART, past 4 weeks (N=136) n (%) | Unadjusted OR (95% CI) | p-value | Adjusted OR (95% CI) | p-value |
|--|--|------------------------|---------|----------------------|---------|
| Several times a week | 11 (8.2) | 3.58 (1.61–7.96)* | 0.002 | 2.31 (1.44–3.71)* | 0.001 |
| IV drug use past month | | | | | |
| No | 117 (94.4) | 1.00 | | | |
| Yes | 7 (5.7) | 1.81 (0.73–4.46) | 0.198 | | |
| Most recent sex partner, past 3 months | | | | | |
| No partner | 16 (19.3) | 1.00 | | | |
| Steady partner | 65 (78.3) | 0.79 (0.42–1.47) | 0.453 | | |
| Casual partner | 2 (2.4) | 0.69 (0.14–3.55) | 0.874 | | |
| Condoms at last intercourse | | | | | |
| Yes | 69 (81.2) | 1.00 | | | |
| No | 16 (18.8) | 1.17 (0.63–2.17) | 0.622 | | |
| HIV transmission route | | | | | |
| Heterosexual sex | 48 (35.6) | 1.00 | | | |
| Homosexual sex | 13 (9.6) | 1.05 (0.53–2.07) | 0.889 | | |
| Intravenous drug use | 32 (23.7) | 1.39 (0.84–2.30) | 0.200 | | |
| Transfusion | 16 (11.9) | 1.11 (0.59–2.09) | 0.740 | | |
| Not sure/other | 26 (19.3) | 0.91 (0.54–1.54) | 0.728 | | |
| Received risk reduction counseling at ART initiation | | | | | |
| Yes | 123 (91.1) | 1.00 | | | |
| No | 12 (8.9) | 0.87 (0.56–1.35) | 0.519 | | |
| Most recent CD4 count | | | | | |
| 200 cells/mm ³ | 93 (68.4) | 1.00 | | | |
| 200 cells/mm ³ | 43 (31.6) | 1.11 (0.74–1.67) | 0.607 | | |
| Time on ART | | | | | |
| < 1 year | 35 (25.7) | 1.00 | | 1.00 | |
| 1 to 3 years | 63 (46.3) | 1.82 (1.15–2.87)* | 0.010 | 1.76 (1.10–2.84)* | 0.020 |
| > 3 years | 38 (27.9) | 1.38 (0.84–2.28) | 0.209 | 1.26 (0.75–2.12)* | 0.384 |
| Tested positive, any STD | | | | | |

| Characteristic | Missed ART, past 4 weeks (N=136) n (%) | Unadjusted OR (95% CI) | p-value | Adjusted OR (95% CI) | p-value |
|----------------|--|------------------------|---------|----------------------|---------|
| No | 122 (89.7) | 1.00 | | | |
| Yes | 14 (10.3) | 1.17 (0.63 –2.19) | 0.617 | | |

* Statistically significant at the p<0.1 level.

[†] Includes those previously married then separated, divorced or widowed.

Table 3
Factors associated with missing at least four weeks of ART in the past year

| Characteristic | Missed 4 weeks of ART, past year (N=49) n (%) | Unadjusted OR (95% CI) | p-value | Adjusted OR (95% CI) | p-value |
|------------------------|---|------------------------|---------|----------------------|---------|
| Age | | | | | |
| 30 years | 7 (14.3) | 1.00 | | | |
| 31 to 40 years | 15 (30.6) | 0.91 (0.36–2.30) | 0.844 | | |
| 41 years | 27 (55.1) | 1.78 (0.75–4.22) | 0.188 | | |
| Sex | | | | | |
| Female | 14 (28.6) | 1.00 | | 1.00 | |
| Male | 35 (71.4) | 1.70 (0.90–3.23) | 0.103 | 2.06 (1.07–3.96)* | 0.031 |
| Residence | | | | | |
| Guangzhou | 17 (36.2) | 1.00 | | | |
| Other, Guangdong | 30 (63.8) | 1.06 (0.57–1.97) | 0.854 | | |
| Education | | | | | |
| Post-secondary | 1 (2.0) | 1.00 | | 1.00 | |
| High school | 5 (10.2) | 2.94 (0.34–25.58) | 0.329 | 3.03 (0.35–26.57)* | 0.318 |
| Middle school | 23 (46.9) | 6.23 (0.83–46.83) | 0.076 | 6.55 (0.87–49.64)* | 0.069 |
| Primary school | 20 (40.8) | 12.82 (1.69–97.42) | 0.014 | 14.31 (1.86–110.27)* | 0.011 |
| Employment | | | | | |
| Full-time | 8 (16.3) | 1.00 | | | |
| Part-time or temporary | 16 (32.7) | 2.57 (1.07–6.16)* | 0.035 | | |
| Retired | 2 (4.1) | 1.28 (0.26–6.25) | 0.763 | | |
| No employment | 23 (46.9) | 2.47 (1.08–5.64)* | 0.032 | | |
| Cohabiting | | | | | |
| Yes | 29 (59.2) | 1.00 | | | |
| No | 20 (40.8) | 1.15 (0.64–2.08) | 0.643 | | |
| Alcohol | | | | | |
| None | 34 (70.8) | 1.00 | | | |

| Characteristic | Missed 4 weeks of ART, past year (N=49) n (%) | Unadjusted OR (95% CI) | p-value | Adjusted OR (95% CI) | p-value |
|--|---|------------------------|---------|----------------------|---------|
| Several times a month | 11 (22.9) | 1.60 (0.78–3.26) | 0.200 | | |
| Several times a week | 3 (6.3) | 2.05 (0.58–7.22) | 0.264 | | |
| IV drug use, past month | | | | | |
| No | 43 (95.6) | 1.00 | | | |
| Yes | 2 (4.4) | 1.21 (0.28–5.34) | 0.800 | | |
| Most recent sex partner, past 3 months | | | | | |
| No partner | 4 (16.0) | 1.00 | | | |
| Steady partner | 20 (80.0) | 1.05 (0.35–3.20) | 0.929 | | |
| Casual partner | 1 (4.0) | 1.58 (0.19–13.08) | 0.673 | | |
| Condoms at last intercourse | | | | | |
| Yes | 21 (84.0) | 1.00 | | | |
| No | 4 (16.0) | 0.91 (0.30–2.74) | 0.865 | | |
| HIV transmission route | | | | | |
| Heterosexual sex | 18 (37.5) | 1.00 | | | |
| Homosexual sex | 7 (14.6) | 1.59 (0.63–3.99) | 0.323 | | |
| Intravenous drug use | 9 (18.8) | 1.00 (0.43–2.28) | 0.992 | | |
| Transfusion | 5 (10.4) | 0.94 (0.34–2.62) | 0.903 | | |
| Not sure/other | 9 (18.8) | 0.86 (0.38–1.98) | 0.727 | | |
| Received risk reduction counseling at ART initiation | | | | | |
| Yes | 46 (93.9) | 1.00 | | | |
| No | 3 (6.1) | 0.58 (0.17–1.91) | 0.369 | | |
| Most recent CD4 count | | | | | |
| 200 cells/mm ³ | 34 (69.4) | 1.00 | | | |
| < 200 cells/mm ³ | 15 (30.6) | 1.03 (0.55–1.93) | 0.936 | | |
| Time on ART | | | | | |
| < 1 year | 11 (22.5) | 1.00 | | 1.00 | |
| 1 to 3 years | 26 (53.1) | 2.14 (1.03–4.43)* | 0.042 | 1.91 (0.91–4.01)* | 0.088 |
| > 3 years | 12 (24.5) | 1.26 (0.54–2.93) | 0.588 | 1.15 (0.49–2.72) | 0.742 |
| Tested positive, any STD | | | | | |

| Characteristic | Missed 4 weeks of ART, past year (N=49) n (%) | Unadjusted OR (95% CI) | p-value | Adjusted OR (95% CI) | p-value |
|----------------|---|------------------------|---------|----------------------|---------|
| No | 44 (89.8) | 1.00 | | | |
| Yes | 5 (10.2) | 1.15 (0.44–3.02) | 0.776 | | |

* Statistically significant at the p<0.1 level